UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
August 25, 2016
Date of Report (Date of earliest event reported)
Immune Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Florida | 000-54933 | 59-3226705 | ||
(State
or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No. |
37 North Orange Ave, Suite 607, Orlando, FL | 32801 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code 888-613-8802
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] | Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On August 25, 2016, Immune Therapeutics, Inc. notified warrant holders that have current warrants with an exercise price of $1.00 that their warrants have been extended until December 31, 2018 pursuant to board action.
All other terms of the warrants remain the same. The expiration date of all warrants expiring after December 31, 2018 has not been changed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNE THERAPEUTICS, INC. | ||
Date: August 29, 2016 | By: | /s/ Noreen Griffin |
Noreen Griffin, CEO |